Bean Therapeutics

Beam Therapeutics is a clinical-stage biotechnology company pioneering the use of base editing to develop a new class of precision genetic medicines. Headquartered in Cambridge, Massachusetts, the company utilizes its proprietary platform to make permanent, single-base changes to the genome without the need for double-strand DNA breaks. Its lead clinical programs include BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency, both of which leverage advanced lipid nanoparticle delivery systems. Beam's technology suite also encompasses ex vivo cell therapies and in vivo liver-targeted treatments, supported by a robust internal manufacturing infrastructure. Founded by world-renowned experts in CRISPR and genome editing, the company has established strategic partnerships with industry leaders like Pfizer and Apellis. Beam is publicly traded on the NASDAQ under the symbol BEAM and continues to expand its pipeline across hematology, oncology, and rare genetic disorders.